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a malignant potential in image inspectionIntroduction
A serous cystadenoﬁbroma is a relatively rare ovarian epithelial
tumor.1 Only one case of paraovarian serous cystadenoﬁbroma has
been reported.2 The appearance of a cystadenoﬁbroma on imaging
is often complicated; cystic- to solid-appearing masses may be
visualized, and it often resembles a malignant tumor.3e5 We herein
present a case of paraovarian serous cystadenoﬁbroma that could
be treated by laparoscopy. Written informed consent was obtained
from the patient for publication of this case. The local Institutional
Review Board exempted our case from the need for approval.Case Report
A 25-year-old woman was referred to our hospital for a parao-
varian tumor with a small solid component.
Her heightwas 158 cm, and sheweighed 73 kg (bodymass index:
29.2 kg/m2). The uterus was normal and the bilateral adnexa were
not palpable. The tumor markers were all in the normal range
(CA125: 13 U/mL; CA19-9: 18 U/mL; and Carcinoembryogenic anti-
gen (CEA): 1.3 ng/mL). Transvaginal ultrasonography (USG,
Figure 1A) and contrast-enhanced pelvic magnetic resonance imag-
ing (MRI, Figure 1B) revealed a 30-mmcysticmass near the left ovary
with a thickenedwall and a small solid component, but therewas no
contrast enhancement or high diffusionweighted imaging signal on
MRI. The appearancewas not clearly malignant, andwe ﬁnally diag-
nosed a paraovarian cyst. Three months later, the size of the tumor
reached 40 mm. We performed 18F-ﬂuorodeoxyglucose positron
emission tomography/computed tomography (FDG-PET/CT). This
showed aweak positive uptake of FDG [maximum standardized up-
take value (SUVmax) ¼ 3.5] at the thickened wall segment
(Figure 1C). It was difﬁcult to exclude the possibility of a malignant
or borderline malignant tumor. However, this tumor appeared to
be paraovarian, so we performed laparoscopic tumor excision.
Laparoscopy revealed an approximately 40-mm left paraovarian
tumor with a small nodule on the surface (Figure 2A). The tumor
was adherent to the left tube, ovary, and mesentery. The tumor
was removed with the left fallopian tube without rupture after
exfoliation.
On macroscopic examination, there were small papillary struc-
tures on the surface and inside the tumor (Figure 2B). MicroscopicConﬂicts of interest: The authors have no conﬂicts of interest relevant to this
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columnar, ciliated cells. The stroma contained spindly ﬁbroblasts.
There was no atypia or architectural complexity. Accordingly, the
tumor was ﬁnally diagnosed as a paraovarian serous cystadenoﬁ-
broma (Figure 2C).Discussion
Ovarian cystadenoﬁbroma is a surface epithelial tumor that
contains ﬁbrous components. It is classiﬁed into serous, endome-
trioid, mucinous, clear cell, and mixed categories, according to
the epithelial cell type. The serous type is the most common
(75%). The susceptible age for this tumor is between 40 years and
50 years, and it is rare at younger ages.1,2
It is often diagnosed preoperatively as a malignancy because of a
solid component or irregular thick septa. Preoperative USG appear-
ance of ovarian cystadenoﬁbroma has been reported.3,4 Cystadeno-
ﬁbroma is cystic and thin walled, and contains simple cysts with
solid nodules. Septation appears in 30.4%, and solid nodules in
56.5e80%3,4 of the cases. The most frequent appearance is a uniloc-
ular, complex cystic tumor (43.4%). The usefulness of color Doppler
sonography to evaluate the vascularity of the cyst wall, septum, or
solid component has been reported.3
The diagnosis of cystadenoﬁbroma using CT has also been
reported.1 Sixteen cases of cystadenoﬁbroma that were diagnosed
pathologically after surgery had all been diagnosed as malignant
or borderline malignant tumors by preoperative examination using
CT, because of a solid component or wall thickening.1
In this case, we could not exclude the possibility of malignancy
or borderline malignancy by USG, CT, and MRI. Thus, we performed
FDG-PET/CT. Recently, the usefulness of FDG-PET/CT for differenti-
ating ovarian cancer from borderline or benign tumors has been
reported.6e8 The mean SUVmax of borderline malignant tumors
was 3.6, and 70% of them showed positive uptake elsewhere in
the tumor; focally increased SUVmax (>5) in a tumor was consid-
ered positive for malignancy.8 In this case, SUVmax of the tumor
was not as strong, so we considered this tumor to be nonmalignant
based on FDG-PET/CT ﬁndings.
In these circumstances, preoperative differential diagnosis to
exclude malignancy or borderline malignancy is difﬁcult with
cystadenoﬁbromas. Preoperative diagnosis of an ovarian tumor,
particularly in a young woman, should be performed carefully to
preserve fertility, and ongoing data collection with combined diag-
nostic imaging and histopathology is important.ally Invasive Therapy. Published by Elsevier Taiwan LLC. This is an open access article under
Figure 1. Preoperative images of paraovarian cystadenoﬁbroma. (A) A small cyst is located next to the left ovary and the white arrow shows the solid part of the tumor, by trans-
vaginal ultrasonography. (B) Contrast-enhanced pelvic MRI shows a simple cystic mass with a thick wall (white arrow) next to the left ovary. (C) FDG-PET/CT shows a weak positive
uptake of FDG (yellow arrow) at the left adnexal lesion. CT ¼ computed tomography; FDG-PET ¼ 18F-ﬂuorodeoxyglucose positron emission tomography; MRI ¼magnetic resonance
imaging.
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Figure 2. Operative and postoperative ﬁndings of paraovarian cystadenoﬁbroma.
(A) The tumor was diagnosed as a paraovarian tumor and the left ovary was normal
on laparoscopy. (B) Macroscopic examination revealed small papillary structures on
the surface and inside the tumor. (C) Microscopic diagnosis was paraoophoritic serous
cystadenoﬁbroma (unilocular cyst lined by a single layer of tall, columnar, ciliated cells
without atypia and architectural complexity and spindly ﬁbroblasts in the stroma).
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